Windtree Therapeutics Inc (WINT)

[H2R]

WINT Catalysts

http://windtreetx.investorroom.com/2017-03-31-Windtree-Therapeutics-Reports-Fourth-Quarter-2016-Financial-Results-and-Provides-Key-Business-Updates

Top Line Data may be great catalysts for WINT:

Enrollment in the AEROSURF® phase 2b clinical trial in up to 240 premature infants 28 to 32 week gestational age for respiratory distress syndrome (RDS) is progressing and the Company reaffirms its plan to announce top-line results from this study in mid-year 2017.

Enrollment in the third dose group of the AEROSURF phase 2a clinical trial in 48 premature infants 26 to 28 week gestational age for RDS is progressing. This study is designed to evaluate safety and tolerability of AEROSURF. Due to a lower number of premature infants who are eligible for enrollment in this age range, enrollment has required additional time and the Company now expects to complete enrollment and announce top-line results in mid-second quarter of 2017.